Abstract: This disclosure relates to olefin polymerization catalysts and compositions, their manufacture, and the production of polyolefins using specific catalyst compositions, including the use of chain shuttling agents in the olefin polymerization process. Specifically, this disclosure provides for dual headed and multi-headed chain shuttling agents (CSAs or MSAs) and for their use in preparing blocky copolymers. By controlling the ratio of dual-headed and multi-headed CSA sites to mono-headed CSA sites, a blocky copolymer can be provided having properties such as a narrow molecular weight distribution and/or improved melt properties.

Abstract: The invention is a two part polymerizable composition comprising in one part an organoboron compound capable of forming free radical generating species amine complex and in the second part one or more compounds capable of free radical polymerization and a cure accelerator comprising a) at least one compound containing a quinone structure or b) at least one compound containing at least one aromatic ring and one or more, preferably two substituents on the aromatic ring selected from hydroxyl, ether and both, where there are two substituents they are located either ortho or para with respect to one another and a peroxide containing compound. The second part may further contain an agent capable of causing the organoboron compound to form free radical generating species upon contacting the two parts. The first part may further comprises one or more compounds capable of free radical polymerization. This facilitates formulating compositions that have commercially desirable volumetric ratios of the two parts.

Abstract: A radical polymerizable composition includes a radical polymerizable compound and an organoborane-azole complex. The organoborane-azole complex includes an azole having at least two nitrogen atoms wherein at least one nitrogen atom is an sp3 nitrogen atom and is substituted. A method of forming the composition includes the step of combining the radical polymerizable compound and the organoborane-azole complex to form the composition. The method also includes the step of polymerizing the composition. A composite article which includes a substrate and a cured composition disposed on the substrate is also provided. The cured composition is formed from polymerization of the composition.

Abstract: A fluorine-containing polymer comprising a fluoroalkyl alcohol (meth)acrylic acid derivative represented by a general formula, CnF2n+1(CH2CF2)a(CF2CF2)b(CH2CH2)cOCOCR?CH2 (in the formula, R is a hydrogen atom or a methyl group, n is an integer of 1 to 6, preferably 2 to 4, a is an integer of 1 to 4, b is an integer of 0 to 3, and c is an integer of 1 to 3) containing in 5 to 100 wt % as a polymerization unit. A organic solvent solution or aqueous dispersion of the fluorine-containing polymer is effectively used as, for example, a surface-modifying agent such as a water- and oil-repellent or an oil barrier.

Abstract: A polymer comprising a conducting or semiconducting segment coupled to a polymer segment having an insulating polymer backbone, the polymer further comprising a RAFT functional group coupled to the polymer segment, wherein there is no RAFT functional group in between the conducting or semiconducting segment and the polymer segment.

Abstract: An ethylene-?-olefin copolymer wherein the copolymer has a monomer unit based on ethylene and a monomer unit based on an ?-olefin having 3 to 20 carbon atoms, the density (d) is 860 to 950 kg/m3, the melt flow rate (MFR) is 1 to 100 g/10 min, the flow activation energy (Ea) is 60 kJ/mol or more, the ratio (Mw/Mn) of the weight average molecular weight (Mw) to the number average molecular weight (Mn) is 5.5 to 30, the ratio (Mz/Mw) of the Z average molecular weight (Mz) to the weight average molecular weight (Mw) is 2 to 5, and the swell ratio (SR) is 1.55 or more and less than 1.8.

Abstract: Ethylene propylene copolymers, substantially free of diene, are described. The copolymers will have a uniform distribution of both tacticity and comonomer between copolymer chains. Further, the copolymers will exhibit a statistically insignificant intramolecular difference of tacticity. The copolymers are made in the presence of a metallocene catalyst.

Abstract: A synthetic method for preparing dual curable (e.g., thermal and light curable) silicone compositions is provided. The first step being a chemical modification of silanichydride bonds in cyclic siloxane monomer by the hydrosilylation reaction with acrylate-/methacrylate-containing allylic monomer. The second step being a ring-opening polymerization of the acrylate-/methacrylate-functionalized cyclic siloxane monomer with siloxane monomers using an oligosiloxane as a chain terminator.

Abstract: This invention relates to a process to functionalize polyolefins comprising contacting a metallocene catalyst with a hydrosilane, and one or more vinyl terminated polyolefins. This invention further relates to the hydrosilane-functionalized polyolefins produced thereby.

Abstract: A method is presented for making an amino alkoxy-modified silsesquioxane (amino AMS) comprising one or more compounds selected from the group consisting of an amino-AMS, an amino/mercaptan co-AMS, an amino/blocked mercaptan co-AMS, and mixtures of these. The use of solid strong cationic catalysts in this reaction system is advantageous because the catalyst remains as a solid throughout the reaction, allowing simplified separation of the solid catalyst from the soluble amino AMS or amino co-AMS products, resulting in total or near total recovery of the amino AMS or amino co-AMS products, as well as virtual total recovery of the catalyst for recycling. The use of the solid strong cationic catalysts is advantageous because it results in amino AMS products that are free of, or substantially free of, residual acid catalyst.

Abstract: A poly(phthalazinone sulfone) composition for molded articles having such characteristics as high temperature resistance, good electrical properties, good chemical and solvent resistance and toughness consists essentially of a polymer of formula (I): Cp-ZxA-Zy??(I) wherein Z is a bisphenyl sulfone moiety of formula: (II): A is a phthalazinone moiety of formula (III): Cp is A, as defined above, or a biphenol moiety of formula (IV): x is an integer of at least 1; y is an integer of at least 1; and x+y=n, where n is an integer such that the polymer has a weight average molecular weight of about 20,000 to about 170,000, the composition comprising less than 5%, by weight, of low molecular weight oligomers; and having a glass transition temperature (Tg) from 225 to 305° C.

Abstract: The present invention provides a method for producing a liquid-crystalline polyester, which comprises melt-polymerizing monomers in a reactor having a draw outlet to obtain a polymer melt and drawing the polymer melt through the draw outlet, characterized in that the monomers comprise a compound selected from an aromatic hydroxycarboxylic acid and derivatives thereof, a compound selected from an aromatic dicarboxylic acid and derivatives thereof and a compound selected from an aromatic diol, an aromatic hydroxyamine, an aromatic diamine and derivatives thereof; the amount of units derived from a compound containing a 1,2-phenylene and/or a 1,3-phenylene skeleton(s) in the polyester is from 0 to 10 mol %; the melt polymerization is performed in the presence of a heterocyclic compound containing two or more nitrogen atoms; and the polymer melt has a flow initiation temperature of from 220 to 250° C.

Abstract: A method polymerizes a monomer to form a polyamide having a reagent incorporated therein. In the method, a masterbatch is formed that includes the reagent. The masterbatch and the monomer are introduced into a reactor, and the monomer is polymerized in the presence of the reagent to form the polyamide having the reagent incorporated therein. The monomer may be a caprolactam monomer that may be polymerized in a VK tube reactor to form polyamide 6 having at least one free acid site. The reagent may be present in an amount of from 1 to 10 parts by weight per 100 parts by weight of the masterbatch. Additionally, the masterbatch and caprolactam may be introduced into the top of the VK tube reactor.

Abstract: The present disclosure provides copolymers of 2-substituted-2-oxazolines possessing two or three reactive functional groups which are also chemically orthogonal. The copolymers described may be random copolymers, block copolymers or a mixture of random and block copolymer configurations. Furthermore, the present disclosure provides novel methods for synthesizing the above polymers and for conjugating to molecules such as targeting, diagnostic and therapeutic agents.

Abstract: The disclosures herein relate to a polymer such as nylon 66, having low yellowness and excellent whiteness retention for applications in melt extrusion and injection molding where an increase in molecular weight is not desirable. The polymer is prepared with a phosphorus compound content, e.g., a sodium hypophosphite (SHP) content, in an amount of 150 to 300 ppm by weight. The presence of an “end cap” additive such as one selected from acetic acid, propionic acid, benzoic acid, or succinic acid, added at the start of polymerization, effectively mitigates undesired molecular weight gain.

Abstract: A photovoltaic device has a high photoelectric conversion efficiency with a material for a photovoltaic device including an electron donating organic material having a structure represented by Formula (1):

Abstract: The invention relates to a process for coupling thiophene or selenophene compounds, in particular for preparing conjugated thiophene or selenophene polymers with high molecular weight and high regioregularity, and to novel polymers prepared by this process. The invention further relates to the use of the novel polymers as semiconductors or charge transport materials in optical, electrooptical or electronic devices including field effect transistors (FETs), thin film transistors (TFT), electroluminescent, photovoltaic and sensor devices. The invention further relates to FETs and other semiconducting components or materials comprising the novel polymers.

Abstract: The invention relates to reactive, urea-bonded alkoxysilanes based on polyether block copolymers reacted with diisocyanate, said copolymers being of the structure B-An in which the central block B consists of polyoxytetramethylene, polyoxyethylene, polybutadiene, polyisoprene, polyacrylate, polymethacrylate, polyamide, polyurethane or polyester units and the blocks A consist of polyoxypropylene units, and to a method for producing such alkoxysilanes. Preparations containing one or more urea-bonded alkoxysilanes can be used as an adhesive, sealant or coating agent.

Abstract: A process for the preparation of a polyol which includes reacting an amino-group-containing starter compound with an alkylene oxide in the presence of a catalyst to form a polyol, wherein the catalyst is based on a compound selected from the group consisting of alkali metal hydroxides, alkali, alkaline earth metal hydrides, alkaline earth metal carboxylates, and alkaline earth hydroxides, and wherein the catalyst is present in an amount of from 0.004 to 0.1 wt. % based on the amount of polyol; and neutralizing the polyol with from 0.75 to 1 mol of sulfuric acid per mol of catalyst used.

Abstract: The present invention provides synthetic cell platforms. The synthetic cell platforms can be used for culturing cells in vitro. The synthetic cell platforms can also be implanted together with bound cells into an individual. The present invention provides methods of using the platforms to provide cells or progeny of such cells for use in various applications, including clinical applications; and methods of use of the platforms to introduce cells into an individual.

Abstract: The present invention provides a method of treating cancer involving administering an insulin-like growth factor-1 receptor (IGF-1 receptor) agonist and an anti-cancer chemotherapeutic agent. Also provided are compounds for treating cancer comprising an IGF-1-receptor ligand coupled to an anti-cancer chemotherapeutic agent. Also provided are compounds for treating cancer comprising an insulin-receptor ligand coupled to an anti-cancer chemotherapeutic agent.

Abstract: The invention relates to antibody compositions and use of the composition to detect disease processes associated with elaboration of proteases. The reagents are directed to assessing an IgG breakdown product that is the result of such proteolytic cleavage. The invention further relates to the use of a therapeutic immunospecific for IgG protease cleavage products to restore effector function to antibody compositions that are subject to protease cleavage.

Abstract: The present invention relates to immunogenic peptides and their various applications. In particular the invention relates to immunogenic peptides derived from the PASD1 protein and their use in therapeutic, diagnostic and prognostic methods.

Abstract: HER2 binding polypeptides comprising the amino acid sequence EX1 RNAYWEIA LLPNLTNQQK RAFIRKLYDD PSQSSELLX2E AKKLNDSQ wherein X1 in position 2 is M, I or L, and X2 in position 39 is S or C (SEQ ID NO: 1) are disclosed. Moreover, such peptides comprising a chelating environment are disclosed. Also radiolabeled polypeptides formed by the peptides comprising a chelating environment and radionuclides are disclosed. Furthermore, methods of in vivo imaging of the body of a mammalian subject having or suspected of having a cancer characterized by overexpression of HER2 comprising administration of such a radiolabeled polypeptide followed by obtainment of an image of the body using a medical imaging instrument and also methods of treating such cancer are disclosed. Furthermore, the use of such a radiolabeled polypeptide in diagnosis and treatment of cancer characterized by overexpression of HER2.

Abstract: Disclosed herein are sweet proteins that are variants of Brazzein, and nucleotide sequences capable of expressing them. Through a replacement of a tyrosine residue at the C terminus in the naturally occurring Brazzein sequence, or the insertion of two residues (at least one being isoleucine, glycine or proline) before the N terminus of wild type Brazzein, sweetness potency, the taste profile and sweetness strength are improved.

Abstract: Methods and compounds for decreasing MARCKS-related inflammation and MARCKS-related mucus hypersecretion or decreasing MARCKS-related inflammation in a subject by the administration of a N-terminal myristoylated protein fragment of the N-terminal region of MARCKS protein or a peptide fragment thereof are disclosed.

Abstract: A purified DOC1 polypeptide comprising a fragment of SEQ ID NO: 1 is provided, wherein the DOC1 polypeptide is not the full-length DOC1 polypeptide sequence. A method of inhibiting angiogenesis in a subject is provided comprising administering to a subject a nucleic acid encoding a DOC1 polypeptide, whereby a cell in the subject produces the DOC1 polypeptide, thus inhibiting angiogenesis. A method of inhibiting tumor growth in a subject is provided comprising administering to a subject a nucleic acid encoding a DOC1 polypeptide, whereby a cell in the subject produces the DOC1 polypeptide, thus inhibiting tumor growth.

Abstract: Described are silk proteins derived from spider mite, more specifically derived from Tetranychus urticae. More specifically, described is the use of these proteins to make fibers, or fiber-composed material and the resulting fibers and materials.

Abstract: A pharmaceutical agent for treating a disease such as inflammatory diseases, blood coagulation diseases associated with deficiency of Protein S has been required. The present invention provides a Protein S composition comprising recombinant Protein S molecules having complex type N-glycoside-linked sugar chains, wherein the Protein S has a higher binding activity to a receptor for advanced glycation end products (hereinafter referred to as “RAGE”) than native Protein S present in healthy human blood, and also has a higher ratio of sugar chains in which fucose is not bound to the complex type N-glycoside-linked sugar chains bound to Protein S than native Protein S present in healthy human blood.

Abstract: The present invention relates to novel regulatory T cell proteins. One protein, designated PD-L3, resembles members of the PD-L1 family, and co-stimulates ?CD3 proliferation of T cells in vitro. A second, TNF-like, protein has also been identified as being upregulated upon ?CD3/?GITR stimulation. This protein has been designated Treg-sTNF. Proteins, antibodies, activated T cells and methods for using the same are disclosed. In particular methods of using these proteins and compounds, preferably antibodies, which bind or modulate (agonize or antagonize) the activity of these proteins, as immune modulators and for the treatment of cancer, autoimmune disease, allergy, infection and inflammatory conditions, e.g. multiple sclerosis is disclosed.

Abstract: The present disclosure provides compositions and methods of use involving binding proteins, e.g., antibodies and antigen-binding fragments thereof, that bind to the matrix metalloproteinase-9 (MMP9) protein (MMP9 is also known as gelatinase-B), wherein the binding proteins comprise an immunoglobulin (Ig) heavy chain (or functional fragment thereof) and an Ig light chain (or functional fragment thereof).

Abstract: The present invention provides a method for enhancing an immune response in a mammal to facilitate the elimination of a chronic pathology. The method involves the removal of immune system inhibitors such as soluble TNF receptor from the circulation of the mammal, thus, enabling a more vigorous immune response to the pathogenic agent. The removal of immune system inhibitors is accomplished by contacting biological fluids of a mammal with one or more binding partner(s) such as TNF? muteins capable of binding to and, thus, depleting the targeted immune system inhibitor(s) from the biological fluids. Particularly useful in the invention is an absorbent matrix composed of an inert, biocompatible substrate joined covalently to a binding partner, such as a TNF? mutein, capable of specifically binding to a targeted immune system inhibitor such as soluble TNF receptor.

Abstract: The configuration of a feedstock material is controlled by bringing it into contact with at least a first gas moving against it at a location with an area and thickness of the feedstock liquid that forms drops or fibers of a selected size. In one embodiment, drops of agricultural input materials are formed for spraying on agricultural fields. In another embodiment, nanofibers of materials such as chitosan or metals are formed. In another embodiment seeds are planted with gel.

Abstract: The present invention relates to compositions and methods for expressing mini-dystrophin peptides. In particular, the present invention provides compositions comprising nucleic acid sequences that are shorter than wild-type dystrophin cDNA and that express mini-dystrophin peptides that function in a similar manner as wild-type dystrophin proteins. The present invention also provides compositions comprising mini-dystrophin peptides, and methods for expressing mini-dystrophin peptides in target cells.

Abstract: The invention relates to the use of particles comprising binding ligands and electron transfer moieties (ETMs). Upon binding of a target analyte, a particle and a reporter composition are associated and transported to an electrode surface. The ETMs are then detected, allowing the presence or absence of the target analyte to be determined.

Abstract: The present invention provides methods and compositions for performing illuminated reactions, particularly sequencing reactions, while mitigating and/or preventing photodamage to reactants that can result from prolonged illumination. In particular, the invention provides methods and compositions for incorporating photoprotective agents into conjugates comprising reporter molecules and nucleoside polyphosphates.

Abstract: The disclosure relates to methods and composition for generating nanoscale devices, systems, and enzyme factories based upon a nucleic acid nanostructure the can be designed to have a predetermined structure.

Abstract: The invention relates to new nucleophosmin protein (NPM) mutants, corresponding gene sequences and relative uses thereof for diagnosis, monitoring of minimal residual disease; prognostic evaluation and therapy of the acute myeloid leukaemia (AML).

Abstract: Described herein are nucleic acid modules for cloning, expression and tagging of eukaryotic membrane proteins. The nucleic acid modules include a receptor for advanced glycation end products (RAGE) signal sequence, a nucleic acid sequence encoding a tag and a multiple cloning sequence (MCS). Any membrane protein of interest can be cloned into the MCS for expression in cells. The nucleic acid modules can encode any type of tag, such as an epitope tag or affinity tag. The nucleic acid modules disclosed herein can be used to express any type of membrane protein and are particularly suited to the expression and tagging of Type I and Type III membrane proteins.

Abstract: The present invention features immunogenic compositions based on pre-fertilization or post-fertilization antigens expressed in the circulating gametocytes in the peripheral blood of infected persons or on the malaria parastes' stages of development in the mosquito midgut including extracellular male and female gametes, fertilized zygote and ookinete. The invention also features methods to prevent the transmission of malaria using the immunogenic compositions of the invention.

Abstract: The present invention provides an optimized immobilization antigen cDNA sequence of cryptocaryon irritans, which has been processed codon replacement and caused the cDNA to express in prokaryotic and eukaryotic cell and translate a protein has similar immunogenicity as the immobilization antigen purified from the theront of Cryptocaryon irritans. The present invention further provides a DNA vaccine produced using the cDNA to prevent fish form cryptocaryon irritans infection.

Abstract: The present invention provides regulatory polynucleotide molecules isolated from a 16S rDNA for enhanced expression of heterologous genes. The invention further discloses compositions, polynucleotide constructs, transformed host cells containing the regulatory polynucleotide sequences, and methods for preparing and using the same.

Abstract: The present invention is directed to the diagnosis and treatment of diseases, preferably the inhibition of tumor growth and its progression to metastatic sites, through the inhibition of the action or production of PTHrP, its isoforms or PTHrP signalling. An aspect of the present invention is also directed to methods of inhibiting the PTHrP1-173 isoform through antagonists thereof, including monoclonal antibodies and siRNA directed there against. The invention may be applicable to many disease states, including but not limited to several types of cancer (including epithelial cancers such as breast, lung, colon, pancreatic, ovarian, prostate and squamous as well as melanoma) expressing PTHrP and its isoforms, alone or in combination with other therapeutic agents.

Abstract: The present invention is directed compositions for targeted delivery of RNA interference (RNAi) polynucleotides to hepatocytes in vivo. Targeted RNAi polynucleotides are administered together with co-targeted melittin delivery peptides. Delivery peptides provide membrane penetration function for movement of the RNAi polynucleotides from outside the cell to inside the cell. Reversible modification provides physiological responsiveness to the delivery peptides.

Abstract: The present invention is directed to convertible nucleosides and polymer supported convertible nucleosides for use in SNAr displacement reactions. The convertible nucleosides can be used to synthesize numerous substituted purine and pyrimidine derivatives.

Abstract: Procedure for the preparation of cationic guar having DS comprised between 0.01 and 3, free from boron and suitable for the use in the cosmetic field and in household cleaning products, comprising the following steps: a) 100 parts by weight of guar flour are reacted with 3-chloro-2-hydroxypropyl trimethylammonium chloride and sodium hydroxide in from 5 to 500 parts by weight of a water and alcohol mixture containing from 20 to 50% by weight of water; b) the amount of water and alcohol is regulated in order to obtain a dispersion containing from 65 to 95% by weight of a of water and alcohol mixture containing from 30 to 50% by weight of water and the dispersion is maintained under stirring at temperature comprised between 15 and 40° C. for at least 10 minutes; c) the mixture is filtered under vacuum and dried to obtain the purified cationic guar.

Abstract: Compounds of the formula I: or a pharmaceutically acceptable salt thereof, wherein, R1 is a group of formula A or formula B, and X, R2, R3, R4, R5, R6, Ra and Rb are as defined herein. Also provided are methods of using the compounds for treating diseases mediated by a P2X3 and/or a P2X2/3 receptor antagonist and methods of making the subject compounds.

Abstract: Methods of preparing ZC-423 (I) which result in varying enantiomeric ratios.

Abstract: The present invention provides processes, methods and intermediates for the preparation of 8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine, salts, hydrates and crystal forms thereof which are useful as serotonin (5-HT) receptor agonists for the treatment of, for example, central nervous system disorders such as obesity.

Abstract: This application relates to compounds of the general Formula I and salts thereof, wherein X, R1A, R1B, R2, R3, R4, and R5 are as defined herein. The application also relates to compositions and methods of treatment of hyperproliferative diseases or disorders.